Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value

Recruiting now

Conditions studied: Pulmonary Mucormycosis

In brief

Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients. The role of chest imaging in their diagnosis is well established in the 2020 EORTC/MSGERC criteria, and its use is almost systematic. However, the progression of lung parenchymal involvement and any potential prognostic radiological patterns in the follow-up of these infections are less well understood. This research aims to identify imaging characteristics predictive of favorable or unfavorable outcomes in infected patients, in order to better tailor follow-up and therapeutic options.

Key facts

Study ID

NCT07339800

Run by

University Hospital, Strasbourg, France

People needed

80

Starts

2025-09-18

Expected to finish

2026-09-19

Last updated by the study team

2026-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 years or older
• Treated at Strasbourg University Hospital between January 1, 2009, and June 3, 2025
• With a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria
• Having undergone at least one CT scan including the thoracic region

You may not qualify if…

• No CT scan including the thoracic region
• No diagnosis of probable or proven invasive pulmonary infection with Mucorales (EORTC/MSGERC 2020 criteria)

Where it is running

• Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.